# US 2005/0239886 A1 · Method of suppressing immune response by reducing intracellular content of glutathione in macrophages and monocytes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0239886 A1
- Document ID: US20050239886A1
- Status: Published application
- Kind: A1
- Application number: 11/097,146
- Filed: 2005-04-04
- Published: 2005-10-27
- Earliest claimed: 1997-10-29
- Assignees: Ajinomoto Co., Inc.
- Inventors: Junji Hamuro; Yukie Murata
- Web page: https://patentgrep.com/patent/US20050239886A1

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A23L 33/175: Amino acids
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 31/225: Polycarboxylic acids
- A61K 38/05: Dipeptides
- A61K 38/063: {Glutathione}
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)

## Abstract

A method of suppressing immune responses, comprising administering to a patient in need thereof an effective amount of a composition comprising a substance capable of reducing the content of reductive glutathione in macrophages.

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

A method of inducing a Th2 response in a subject, wherein the subject is suffering from at least one of gastrointestinal inflammatory disease, hepatitis, or hepatic cirrhosis, comprising administering to the subject an effective amount of the cystine derivative represented by formula (I):
wherein
R1 and R2, independently from each other, represent an alkyl group or a substituted alkyl group, and
R3 and R4, independently from each other, represent an acyl group or a peptidyl group.

### Claim 21 (depends on 20)

The method of claim 20, wherein the subject is suffering from gastrointestinal inflammatory disease.

### Claim 22 (depends on 20)

The method of claim 20, wherein the subject is suffering from hepatitis.

### Claim 23 (depends on 20)

The method of claim 20, wherein the subject is suffering from hepatic cirrhosis.

### Claim 24 (depends on 20)

The method of claim 20, wherein the subject is also suffering from rheumatoid arthritis.

### Claim 25 (depends on 20)

The method of claim 20, wherein the intracellular content of reductive glutathione is reduced to at most 0.1 nmoles of glutathione per 5×105 macrophage cells.

### Claim 26 (depends on 20)

The method of claim 20, wherein administration of the cystine deriviative (a) reduces the content of reductive glutathione in macrophages in the subject, (b) increases the capability of the macrophages to produce IL-6, and (b) decreases the capability of the macrophages to produce IL-12 and NO.

### Claim 27 (depends on 20)

The method of claim 20, wherein the alkyl group has 1 to 12 carbon atoms.

### Claim 28 (depends on 20)

The method of claim 20, wherein the acyl group has 1 to 12 carbon atoms.

### Claim 29 (depends on 20)

The method of claim 20, wherein the peptidyl group has 1 to 10 amino acids.

### Claim 30 (depends on 20)

The method of claim 20, wherein IL-4 is also administered to the subject.

### Claim 31 (depends on 20)

The method of claim 20, wherein TGF-beta is also administered to the subject.

### Claim 32 (depends on 20)

The method of claim 20, wherein at least one substance which inhibits the production or the function of IL-12 is also administered to the subject.

### Claim 33

A method of inducing a Th2 response in a subject, comprising administering to the subject an effective amount of the cystine derivative represented by formula (I):
wherein
R1 and R2, independently from each other, represent an alkyl group or a substituted alkyl group, and
R3 and R4, independently from each other, represent an acyl group or a peptidyl group, wherein at least one of R3 and R4 is a peptidyl group having 1 to 10 amino acids.

### Claim 34 (depends on 33)

The method of claim 33, wherein R3 is a peptidyl group having 1 to 10 amino acids.

### Claim 35 (depends on 33)

The method of claim 33, wherein R4 is a peptidyl group having 1 to 10 amino acids.

### Claim 36 (depends on 33)

The method of claim 33, wherein administration of the cystine deriviative (a) reduces the content of reductive glutathione in macrophages in the subject, (b) increases the capability of the macrophages to produce IL-6, and (b) decreases the capability of the macrophages to produce IL-12 and NO.

### Claim 37 (depends on 33)

The method of claim 33, wherein the intracellular content of reductive glutathione is reduced to at most 0.1 nmoles of glutathione per 5×105 macrophage cells.

### Claim 38 (depends on 33)

The method of claim 33, wherein the subject is suffering from chronic rheumatoid arthritis.

### Claim 39 (depends on 33)

The method of claim 33, wherein IL-4 is also administered to the subject.

### Claim 40 (depends on 33)

The method of claim 33, wherein TGF-beta is also administered to the subject.

### Claim 41 (depends on 33)

The method of claim 33, wherein at least one substance which inhibits the production or the function of IL-12 is also administered to the subject.

### Claim 42 (depends on 33)

The method of claim 33, wherein the alkyl group has 1 to 12 carbon atoms.

### Claim 43 (depends on 33)

The method of claim 33, wherein the acyl group has 1 to 12 carbon atoms.

### Claim 44 (depends on 33)

The method of claim 33, wherein the peptidyl group has 1 to 10 amino acids.

### Claim 45 (depends on 33)

The method of claim 33, wherein the acyl group is derived from a hydrocarbon carboxylic acid.

### Claim 46

A method suppressing cellular immune responses in a subject by skewing the Th1/Th2 balance to Th2, wherein the subject is suffering from at least one of gastrointestinal inflammatory disease, hepatitis, or hepatic cirrhosis, comprising administering to the subject an effective amount of the cystine derivative represented by formula (I):
wherein
R1 and R2, independently from each other, represent an alkyl group or a substituted alkyl group, and
R3 and R4, independently from each other, represent an acyl group or a peptidyl group.

### Claim 47 (depends on 46)

The method of claim 46, wherein the subject is suffering from gastrointestinal inflammatory disease.

### Claim 48 (depends on 46)

The method of claim 46, wherein the subject is suffering from hepatitis.

### Claim 49 (depends on 46)

The method of claim 46, wherein the subject is suffering from hepatic cirrhosis.

### Claim 50 (depends on 46)

The method of claim 46, wherein the subject is also suffering from rheumatoid arthritis.

### Claim 51 (depends on 46)

The method of claim 46, wherein the intracellular content of reductive glutathione is reduced to at most 0.1 nmoles of glutathione per 5×105 macrophage cells.

### Claim 52 (depends on 46)

The method of claim 46, wherein administration of the cystine deriviative reduces the content of reductive glutathione in the macrophages in the subject.

### Claim 53 (depends on 46)

The method of claim 46, wherein the alkyl group has 1 to 12 carbon atoms.

### Claim 54 (depends on 46)

The method of claim 46, wherein the acyl group has 1 to 12 carbon atoms.

### Claim 55 (depends on 46)

The method of claim 46, wherein the peptidyl group has 1 to 10 amino acids.

### Claim 56 (depends on 46)

The method of claim 46, wherein IL-4 is also administered to the subject.

### Claim 57 (depends on 46)

The method of claim 46, wherein TGF-beta is also administered to the subject.

### Claim 58 (depends on 46)

The method of claim 46, wherein at least one substance which inhibits the production or the function of IL-12 is also administered to the subject.

### Claim 59

A method of suppressing cellular immune responses in a subject by skewing the Th1/Th2 balance to Th2, comprising administering to the subject an effective amount of the cystine derivative represented by formula (I):
wherein
R1 and R2, independently from each other, represent an alkyl group or a substituted alkyl group, and
R3 and R4, independently from each other, represent an acyl group or a peptidyl group, wherein at least one of R3 and R4 is a peptidyl group having 1 to 10 amino acids.

### Claim 60 (depends on 59)

The method of claim 59, wherein R3 is a peptidyl group having 1 to 10 amino acids.

### Claim 61 (depends on 59)

The method of claim 59, wherein R4 is a peptidyl group having 1 to 10 amino acids.

### Claim 62 (depends on 59)

The method of claim 59, wherein the subject is suffering from rheumatoid arthritis.

### Claim 63 (depends on 59)

The method of claim 59, wherein administration of the cystine deriviative reduces the content of reductive glutathione in the macrophages in the subject.

### Claim 64 (depends on 59)

The method of claim 59, wherein the intracellular content of reductive glutathione is reduced to at most 0.1 nmoles of glutathione per 5×105 macrophage cells.

### Claim 65 (depends on 59)

The method of claim 59, wherein the subject is suffering from chronic rheumatoid arthritis.

### Claim 66 (depends on 59)

The method of claim 59, wherein IL-4 is also administered to the subject.

### Claim 67 (depends on 59)

The method of claim 59, wherein TGF-beta is also administered to the subject.

### Claim 68 (depends on 59)

The method of claim 59, wherein at least one substance which inhibits the production or the function of IL-12 is also administered to the subject.

### Claim 69 (depends on 59)

The method of claim 59, wherein the alkyl group has 1 to 12 carbon atoms.

### Claim 70 (depends on 59)

The method of claim 59, wherein the acyl group has 1 to 12 carbon atoms.

### Claim 71 (depends on 59)

The method of claim 59, wherein the peptidyl group has 1 to 10 amino acids.

### Claim 72 (depends on 59)

The method of claim 59, wherein the acyl group is derived from a hydrocarbon carboxylic acid.
